New Platform CAR-NK
In addition to autologous CAR-T products, MolMed is carrying out in parallel the development of a new platform based on NK cells (Natural Killer) genetically modified with lentiviral vectors, in order to obtain CAR-NK allogeneic products.
Genetically modified NK cells are today considered one of the most interesting and innovative candidates of pre-clinical research in cellular immunotherapy. These cells belong to the innate immune system and are able to mediate the anti-tumor effect without the risk of developing the transplantation disease against the host (GvHD). NK cells are therefore suitable for allogeneic therapy, allowing to treat a large number of individuals affected by cancer starting from a single lot resulting from a healthy donor. This allows to overcome the limits related to personalized autologous therapies, with significant benefits both from a technical and economic point of view.
MolMed has finalized an agreement with Glycostem Therapeutics, a Dutch company that uses a proprietary process of differentiation of CD34 + stem cells into NK cells. Glycostem and MolMed will collaborate synergistically in the development and production of new products made up of CAR-NK cells to recognize different tumor antigens.